Aclarion Implements 1-for-335 Reverse Stock Split to Maintain Nasdaq Listing

Healthcare technology company Aclarion, Inc. (Nasdaq: ACON) has announced a 1-for-335 reverse stock split of its common stock, scheduled to take effect before market open on January 30, 2025. The move represents a strategic effort to maintain the company's Nasdaq listing by boosting its share price above the exchange's required $1.00 minimum bid price.

The dramatic consolidation will see Aclarion's outstanding shares reduced from approximately 169.4 million to around 500,000, with stockholders receiving one new share for every 335 existing shares. The action follows stockholder approval received on December 31, 2024, and includes proportional adjustments to the company's outstanding warrants, stock options, and restricted stock units.

This corporate action carries significant implications for both investors and the company's market presence. For Aclarion, which develops technology for chronic low back pain diagnosis, maintaining its Nasdaq listing is crucial for market visibility and access to capital markets. The reverse split could help stabilize the company's trading status, though it does not directly affect Aclarion's market capitalization or fundamental business operations.

Shareholders holding less than 335 shares will receive one share under the new structure, with all fractional shares being rounded up. The company's shares will trade under a new CUSIP number (655187300), with brokerage accounts automatically adjusting to reflect the split ratio. Current certificate holders will receive exchange instructions from the company's transfer agent, Vstock Transfer.